Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49)

Journal of Urology

Volumn 161, Issue 5, 1999, Pages 1702-1706

  Gunther J H ^a   Frambach, M ^a   Deinert, I ^a   Brandau, S ^a   Jocham, D ^a   Bohle A ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Acetylic salicylic acid; BCG; Bladder neoplasm; Murine; Pentoxifylline

Indexed keywords

ACETYLSALICYLIC ACID; BCG VACCINE; PENTOXIFYLLINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BODY WEIGHT; CANCER ADJUVANT THERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATURIA; INTRAVESICAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH;

EID: 0345425054     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)69008-8     Document Type: Article

References (32)

1. Akaza, H., Iwasaki, A., Ohtani, M., Ikeda, N., Niijima, K., Toida, I. and Koiso, K.: Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guérin to bladder cancer cells. Cancer, 72: 558, 1993.
2. Balazs, C. and Erzsebet, K.: Immunological aspects of the effect of pentoxifylline (trental) - a brief review. Acta Microbiol. Immunol. Hung., 41: 121, 1994.
3. Böhle, A., Balck, F., von Wietersheim, J. and Jocham, D.: The quality of life during intravesical Bacillus Calmette-Guérin therapy. J. Urol., 155: 1221, 1996.
4. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H-D.: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144: 53, 1990.
5. Böhle, A., Thanhäuser, A., Ernst, M., Flad, H.-D., Rüsch-Gerdes, S., Jocham, D. and Ulmer, A. J.: Reduction of side-effects of intravesical therapy with bacillus Calmette-Guérin by Pentoxifyllline? An in vitro approach. Clin. Infect. Dis., 1999.
6. Brandau, S., Rehbein, P., Durek, C., Flad, H-D., Ulmer, A. J., Jocham, D. and Böhle, A.: BCG-immunotherapy of bladder cancer: which drugs reduce side effects without affecting antitumor capacity? An in vitro approach. Br. J. Urol., 80(Suppl.): 35, 1997.
7. Brandau, S., Rehbein, P., Schäfer, I., Durek, C., Jocham, D., Flad, H-D., Ulmer, A. J. and Böhle, A.: In vitro testing of different BCG preparations to reduce side effects of intravesical BCG. Urol. Res., 25: 71, 1997.
8. Brandau, S., Rehbein, P., Schäfer, I., Durek, C., Jocham, D., Flad, H-D., Ulmer, A. J. and Böhle, A.: Intravesical BCG therapy: salicylic acid reduces side effects without affecting anti-tumor capacity in vitro. Urol. Res., 25: 94, 1997.
9. Castro, A. G., Esaguy, N., Macedo, P. M., Aguas, A. P. and Silva, M. T.: Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils in vivo and are infested by attracted granulocytes. Infect. Immun., 59: 3009, 1998.
10. Chin, J. L., Kadhim, S. A., Batislam, E., Karlik, S. J., Garcia, B. M., Nickel, J. C. and Morales, A.: Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J. Urol., 156: 1189, 1996.
11. de Boer, E. C., de Jong, W.: H., van der Meijden, A. P. M., Steerenberg, P. A., Witjes, F., Vegt, P. D. J., Debruyne, F. M. J., and Ruitenberg, E. J.: Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. Urol. Res., 19: 45, 1991.
12. Diaz-González, F. and Sánchez-Madrid, F.: Inhibition of leukocyte adhesion: an alternative mechanism of action for antiinflammatory drugs. Immunol. Today, 19: 169, 1998.
13. Hudson, M. A., Yuan, J. J., Catalona, W. J. and Ratliff, T. L.: Adverse impact of fibrin clot inhibitors on intravesical Bacillus Calmette-Guérin therapy for superficial bladder tumors. J. Urol., 144: 1362, 1991.
14. Sakata, T., Hasegawa, R., Johannson, S. L., Zenser, T. V. and Cohen, S. M.: Inhibition by aspirin of N-(4-(5-nitro-2-furyl)-2-thiazolyl)-formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in F344 rats. Cancer Res., 46: 3906, 1986.
15. Lamm, D. L.: Complications of bacillus Calmette-Guerin immunotherapy. Urol. Clin. N. Am., 19: 565, 1992.
16. Launois, P., Maillere, B., Dieye, A., Sarthou, J. L. and Bach, M. A.: Human phagocyte oxidative burst activation of BCG. M. leprae and atypical mycobacteria: defective activation by M. leprae is not reversed by interferon γ: Cell. Immunol., 124: 168, 1989.
17. Malech, H. L. and Gallin, J. I.: Medical intelligence. Current concepts: immunology - neutrophils in human diseases. New Engl. J. Med., 117: 687, 1987.
18. Mandell, G. L.: Cytokines, phagocytes and pentoxifylline. J. Cardiovasc. Pharmacol., 25: 20, 1995.
19. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O.: Enhanced antitumor effect of Bacillus Calmette-Guerin in combination with fibrinogen on urinary bladder tumor. J. Urol., 151: 1420, 1994.
20. Nseyo, U. O. and Lamm, D. L.: Therapy of superficial bladder cancer. Semin. Oncol., 23: 598, 1996.
21. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F.: Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147: 1636, 1992.
22. Rao, K. V. N., Detrisac, C. J., Steele, V. E., Hawk, E. T., Kelloff, G. J. and McCormick, D. L.: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17: 1435, 1996.
23. Ratliff, T. L., Hudson, M. A. and Catalona, W. J.: Strategy for improving therapy of superficial bladder cancer. World J. Urol., 9: 95, 1991.
24. Shapiro, A., Kelley, D. R., Oakley, D. M., Catalona, W. J. and Ratliff, T. L.: Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guerin. Cancer Res., 44: 3051, 1984.
25. Shapiro, A., Ratliff, T. L., Oakley, D. M. and Catalona, W. J.: Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly 1:C/poly-l-lysine and Cis platinum in murine bladder cancer. J. Urol., 131: 139, 1984.
26. Soloway, M.: Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res., 37: 2918, 1977.
27. Summerhayes, I. C. and Franks, L. M.: Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J. Natl. Cancer Inst., 62: 1017, 1979.
28. Swerdlow, R. D., Ratliff, T. L., Regina, M. L., Ritchey, J. K. and Ebert, R. F.: Immunotherapy with keyhole limpet hemocyanin: efficacy and safety in the MB-49 intravesical murine bladder tumor model. J. Urol., 151: 1718, 1994.
29. Thanhäuser, A., Reiling, N., Böhle, A., Toellner, K-M., Duchrow, M., Scheel, D., Schlüter, C., Ernst, M., Flad, H-D. and Ulmer, A. J.: Pentoxifylline: a potent inhibitor of IL-2 and IFN-τ biosynthesis and bacillus BCG-induced cytotoxicity. Immunology, 80: 151, 1993.
30. van der Sloot, E., Kuster, S., Böhle, A., Braun, J. and Wood, W. G.: Towards an understanding of the mode of action of bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin. Eur. J. Clin. Chem. Clin. Biochem., 30: 503, 1992.
31. Ward, A. and Clissold, S. P.: Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs, 34: 50, 1987.
32. Witjes, J.: A., van der Meijden, A. P. M., Doesburg, W., and Debruyne, F. M.: Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guerin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group. Eur. Urol., 23: 366, 1993